期刊
FUTURE ONCOLOGY
卷 14, 期 5, 页码 417-430出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2017-0436
关键词
esophageal cancer; esophagogastric cancer; gastric cancer; gastroesophageal cancer; immune checkpoint blockade; immunotherapy; MK-3475; pembrolizumab; PD-1; PD-L1
类别
资金
- NIH, USA [NIH K23 CA178203-01A1]
- NATIONAL CANCER INSTITUTE [K23CA178203] Funding Source: NIH RePORTER
Pembrolizumab is a monoclonal antibody directed against PD-1 that is US FDA approved for treatment of advanced PD-L1 positive gastric and gastroesophageal junction adenocarcinoma in patients who have progressed on at least two prior lines of chemotherapy. This article summarizes the clinical evidence regarding safety, tolerability and efficacy of pembrolizumab in this setting. In addition, this article describes the investigational use of pembrolizumab as first- and second-line therapy and in combination with other treatments. Finally, this review compares other checkpoint inhibitors to pembrolizumab for the treatment of this disease, and explores predictive biomarkers of response to PD-1 blockade.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据